Spain's Medicines Watchdog Addresses Hormone Treatment Shortages
What happened
A shortage of Lenzetto, a transdermal estradiol spray, has caused a domino effect across the market for hormone replacement therapies in Spain and other European countries. The national medicines watchdog in Spain, Aemps, has recorded supply issues affecting other treatments such as Evopad, Estradot, and Bijuva. While the Secretary of State for Health stated that supplies should begin to improve in November, Aemps warned that the timetable remains unclear.
From euronews.com
Why it matters
The initial shortage of Lenzetto drove up demand for other estradiol formulations that were not prepared for the surge in need. This situation has resulted in months of supply problems for hundreds of thousands of Spanish women. Aemps also noted that forecasts provided by Lenzetto's manufacturer have not always been accurate.
From euronews.com
Who's involved
- SpainThe country where the hormone treatment shortages are occurring.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ItalySpeculative
Manufacturers' production capacity in several European countries could be strained by the shortage and surge in demand.
Keep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
-
Spain
country in southwestern Europe with territories in Africa